Telix Pharmaceuticals confirms US commercial launch of Illuccix

Latest News

Telix Pharmaceuticals (ASX:TLX) has announced that its prostate cancer imaging agent Illuccix, also known as 68Ga-PSMA-11 injection, is now commercially available in the US.

The company said Illuccix is available to order from 117 Cardinal Health and PharmaLogic pharmacies, delivering coverage to around 85 per cent of PET imaging sites across the US.

The company said United Pharmacy Partners has been added as a third pharmacy network partner on a select basis.

CEO Dr Christian Behrenbruch said, “Physicians across the United States are now able to order doses and schedule patients for Illuccix scans. This important milestone significantly improves access to PSMA-PET imaging across the United States and allows physicians to confidently schedule dose delivery any time of the day, optimising flexibility and control for patients. With the recent approval in the United States of PSMA therapy – and the importance of 68Ga-PSMA-11 for patient selection – it is an exciting time for molecular imaging in GU-Oncology.”

First doses are already being scheduled for April in key academic centres across the US, including the University of Washington.

“We are excited to be one of the first locations to bring this new imaging to our patients,” said Professor of Radiology, Dr Delphine Chen.

“It brings a new dimension to our ability to stage and treat prostate cancer and can ultimately help us improve our ability to manage the full extent of their disease.”